Complete Histologic Response Induced by Sorafenib in Advanced Hepatocellular Carcinoma: A Case Report-Reference-Cited by-同舟云学术

Complete Histologic Response Induced by Sorafenib in Advanced Hepatocellular Carcinoma: A Case Report

Published:2011-04-20 Issue:12 Volume:29 Page:e330-e332
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Curtit Elsa¹,Thiery-Vuillemin Antoine¹,Nguyen Thierry¹,Heyd Bruno¹,Pivot Xavier¹,Di Martino Vincent¹,Borg Christophe²

Affiliation:

1. Centre Hospitalier Universitaire de Besançon, Besançon, France

2. Unité Mixte de Recherche 645, Institut National de la Santé et de la Recherche Médicale/Etablissement Français du Sang/Université de Franche Comté; Centre Hospitalier Universitaire de Besançon, Besançon, France

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.32.6785

Reference7 articles.

1. Sorafenib in Advanced Hepatocellular Carcinoma

2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

3. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

4. Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report

5. Apparent Remission of a Solitary Metastatic Pulmonary Lesion in a Liver Transplant Recipient Treated with Sorafenib

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

2. Liver Resection and Transplantation in the Era of Checkpoint Inhibitors;JHEP Reports;2024-08

3. The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma;Technology in Cancer Research & Treatment;2023-01

4. The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response;Technology in Cancer Research & Treatment;2023-01

5. Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study;Frontiers in Oncology;2022-11-24